FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381469509> ?p ?o ?g. }

• W4381469509 abstract "Plasma ceramide levels (henceforth, “ceramides”) are biomarkers of some diseases that are comorbidities of Down syndrome (DS). We sought to determine if comorbidities in DS were associated with ceramides, studying a convenience cohort of 35 study participants, all ≥12 months old. To identify comorbidities, we reviewed the problem lists in electronic health records that were concurrent with sample collection. We placed clinically related comorbidities into one of five categories of comorbidities, henceforth, categories: obesity/overweight; autoimmune disease; congenital heart disease; bacterial infection; and central nervous system (CNS) condition. We measured the eight ceramides most frequently associated with disease using liquid chromatography–tandem mass spectrometry. We calculated a ceramide composite outcome score (CCOS) for each participant by normalizing each ceramide level to the mean for that level in the study population and then summing the normalized levels, to be proxy variable for all eight ceramides in aggregate. We used multivariable linear regression models adjusted for age and sex to test associations of categories with ceramides and with CCOSs. Post hoc, we realized that co-occurring comorbidities might interfere with establishing associations between predictor categories and ceramides and that stratified analyses might eliminate their influence on associations. We posited that CCOSs could be used to screen for associations of categories with multiple ceramides, since most diseases have been associated with more than one ceramide. We chose to omit in the stratified analyses the two categories that were the most different from one another in their associations with their CCOSs, having the most divergent regression coefficients (the highest positive and lowest negative coefficients). We first omitted one of these two divergent categories in a stratified analysis and tested in the remaining participants (those without a comorbidity in the interfering category) for associations of the other four categories with their CCOSs and then did the same for the other divergent category. In each of these two screening stratified analyses, we found one category was significantly associated with its CCOS. In the two identified categories, we then tested for associations with each of the eight ceramides, using the appropriate stratified analysis. Next, we sought to determine if the associations of the two categories with ceramides we found by omitting participants in the interfering categories held in our small sample for participants in the omitted categories as well. For each of the two categories, we therefore omitted participants without the interfering category and determined associations between the predictor category and individual ceramides in the remaining participants (those with a comorbidity in the interfering category). In the a priori analyses, autoimmune disease was inversely associated with C16 and CNS condition was inversely associated with C23. Obesity/overweight and CNS condition were the two categories with the most divergent regression coefficients (0.037 vs. −0.048). In post hoc stratified analyses, after omitting participants with obesity/overweight, thereby leaving participants without obesity/overweight, bacterial infection was associated with its CCOS and then with C14, C20, and C22. However, in the companion stratified analyses, omitting participants without obesity/overweight, thereby leaving participants with obesity/overweight, bacterial infection was not associated with any of the eight ceramides. Similarly, in post hoc stratified analyses after omitting participants with a CNS condition, thereby leaving participants without a CNS condition, obesity/overweight was associated with its CCOS and then with C14, C23, and C24. In the companion analyses, omitting participants without a CNS condition, thereby leaving participants with a CNS condition, obesity/overweight was inversely associated with C24.1. In conclusion, CNS and autoimmune disease were inversely associated with one ceramide each in a priori analyses. In post hoc analyses, we serendipitously omitted categories that interfered with associations of other categories with ceramides in stratified analyses. We found that bacterial infection was associated with three ceramides in participants without obesity/overweight and that obesity/overweight was associated with three ceramides in participants without a CNS condition. We therefore identified obesity/overweight and CNS conditions as potential confounders or effect modifiers for these associations. This is the first report of ceramides in DS and in human bacterial infection. Further study of ceramides in comorbidities of DS is justified." @default.
• W4381469509 created "2023-06-22" @default.
• W4381469509 creator A5001856843 @default.
• W4381469509 creator A5001965184 @default.
• W4381469509 creator A5034626049 @default.
• W4381469509 creator A5037775852 @default.
• W4381469509 creator A5069088998 @default.
• W4381469509 creator A5071093020 @default.
• W4381469509 creator A5090945180 @default.
• W4381469509 date "2023-06-21" @default.
• W4381469509 modified "2023-09-24" @default.
• W4381469509 title "An exploratory study of plasma ceramides in comorbidities in Down syndrome" @default.
• W4381469509 cites W129245961 @default.
• W4381469509 cites W1570340380 @default.
• W4381469509 cites W1850582709 @default.
• W4381469509 cites W1905885117 @default.
• W4381469509 cites W1959199978 @default.
• W4381469509 cites W1966452335 @default.
• W4381469509 cites W1972660643 @default.
• W4381469509 cites W2011804598 @default.
• W4381469509 cites W2049914201 @default.
• W4381469509 cites W2075200608 @default.
• W4381469509 cites W2086555035 @default.
• W4381469509 cites W2105017519 @default.
• W4381469509 cites W2106574223 @default.
• W4381469509 cites W2164216363 @default.
• W4381469509 cites W2287180374 @default.
• W4381469509 cites W2497007355 @default.
• W4381469509 cites W2515789121 @default.
• W4381469509 cites W2566039789 @default.
• W4381469509 cites W2587127477 @default.
• W4381469509 cites W2704636153 @default.
• W4381469509 cites W2766826848 @default.
• W4381469509 cites W2808313808 @default.
• W4381469509 cites W2888236762 @default.
• W4381469509 cites W2889229374 @default.
• W4381469509 cites W2892135252 @default.
• W4381469509 cites W2901207373 @default.
• W4381469509 cites W2901345444 @default.
• W4381469509 cites W2917899198 @default.
• W4381469509 cites W2958147199 @default.
• W4381469509 cites W2965475701 @default.
• W4381469509 cites W2973013389 @default.
• W4381469509 cites W2976965246 @default.
• W4381469509 cites W2981562683 @default.
• W4381469509 cites W2988406737 @default.
• W4381469509 cites W2991488674 @default.
• W4381469509 cites W2997449152 @default.
• W4381469509 cites W3001230862 @default.
• W4381469509 cites W3022403817 @default.
• W4381469509 cites W3036745810 @default.
• W4381469509 cites W3102920585 @default.
• W4381469509 cites W3160514275 @default.
• W4381469509 cites W3201225897 @default.
• W4381469509 cites W4237822883 @default.
• W4381469509 cites W4281791251 @default.
• W4381469509 doi "https://doi.org/10.1002/ajmg.a.63325" @default.
• W4381469509 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37340831" @default.
• W4381469509 hasPublicationYear "2023" @default.
• W4381469509 type Work @default.
• W4381469509 citedByCount "0" @default.
• W4381469509 crossrefType "journal-article" @default.
• W4381469509 hasAuthorship W4381469509A5001856843 @default.
• W4381469509 hasAuthorship W4381469509A5001965184 @default.
• W4381469509 hasAuthorship W4381469509A5034626049 @default.
• W4381469509 hasAuthorship W4381469509A5037775852 @default.
• W4381469509 hasAuthorship W4381469509A5069088998 @default.
• W4381469509 hasAuthorship W4381469509A5071093020 @default.
• W4381469509 hasAuthorship W4381469509A5090945180 @default.
• W4381469509 hasConcept C126322002 @default.
• W4381469509 hasConcept C151956035 @default.
• W4381469509 hasConcept C190283241 @default.
• W4381469509 hasConcept C2777851122 @default.
• W4381469509 hasConcept C2779134260 @default.
• W4381469509 hasConcept C2780586474 @default.
• W4381469509 hasConcept C2908647359 @default.
• W4381469509 hasConcept C511355011 @default.
• W4381469509 hasConcept C54355233 @default.
• W4381469509 hasConcept C61705674 @default.
• W4381469509 hasConcept C71924100 @default.
• W4381469509 hasConcept C86803240 @default.
• W4381469509 hasConcept C99454951 @default.
• W4381469509 hasConceptScore W4381469509C126322002 @default.
• W4381469509 hasConceptScore W4381469509C151956035 @default.
• W4381469509 hasConceptScore W4381469509C190283241 @default.
• W4381469509 hasConceptScore W4381469509C2777851122 @default.
• W4381469509 hasConceptScore W4381469509C2779134260 @default.
• W4381469509 hasConceptScore W4381469509C2780586474 @default.
• W4381469509 hasConceptScore W4381469509C2908647359 @default.
• W4381469509 hasConceptScore W4381469509C511355011 @default.
• W4381469509 hasConceptScore W4381469509C54355233 @default.
• W4381469509 hasConceptScore W4381469509C61705674 @default.
• W4381469509 hasConceptScore W4381469509C71924100 @default.
• W4381469509 hasConceptScore W4381469509C86803240 @default.
• W4381469509 hasConceptScore W4381469509C99454951 @default.
• W4381469509 hasLocation W43814695091 @default.
• W4381469509 hasLocation W43814695092 @default.
• W4381469509 hasOpenAccess W4381469509 @default.
• W4381469509 hasPrimaryLocation W43814695091 @default.
• W4381469509 hasRelatedWork W1994930795 @default.

• next